Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million in Biobucks

Boehringer Ingelheim based in Ingelheim, Germany, and Epizyme, headquartered in Cambridge, Mass., signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million.